Resistance to clopidogrel: A review of the evidence

Journal of the American College of Cardiology

Volumn 45, Issue 8, 2005, Pages 1157-1164

  Nguyen, Thuy Anh ^a   Diodati, Jean G ^a,b   Pharand, Chantal ^a,b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PURINE P2Y12 RECEPTOR; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART FAILURE; ATHEROMATOSIS; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; UPREGULATION;

EID: 17144370263     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.01.034     Document Type: Review

References (67)

1. A.P. Selwyn Prothrombotic and antithrombotic pathways in acute coronary syndromes Am J Cardiol 91 2003 3H 11H
2. K.H. Mak, G. Belli, S.G. Ellis, D.J. Moliterno Subacute stent thrombosis evolving issues and current concepts J Am Coll Cardiol 27 1996 494 503
3. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
4. D.L. Bhatt, M.E. Bertrand, P.B. Berger Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J Am Coll Cardiol 39 2002 9 14
5. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
6. L. Macchi, L. Christiaens, S. Brabant Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate Thromb Res 107 2002 45 49
7. P. Jaremo, T.L. Lindahl, S.G. Fransson, A. Richter Individual variations of platelet inhibition after loading doses of clopidogrel J Intern Med 252 2002 233 238
8. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, C.M. O'Connor Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
9. P.A. Gurbel, K.P. Bliden Durability of platelet inhibition by clopidogrel Am J Cardiol 91 2003 1123 1125
10. I. Muller, F. Besta, C. Schulz, S. Massberg, A. Schonig, M. Gawaz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 89 2003 783 787
11. D. Soffer, I. Moussa, K.J. Harjai Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 59 2003 21 25
12. D. Woulfe, J. Yang, L. Brass ADP and platelets the end of the beginning J Clin Invest 107 2001 1503 1505
13. B. Stein, V. Fuster, D.H. Israel Platelet inhibitor agents in cardiovascular disease an update J Am Coll Cardiol 14 1989 813 836
14. A.I. Schafer Antiplatelet therapy Am J Med 101 1996 199 209
15. S.P. Kunapuli, R.T. Dorsam, S. Kim, T.M. Quinton Platelet purinergic receptors Curr Opin Pharmacol 3 2003 175 180
16. J. Jin, J.L. Daniel, S.P. Kunapuli Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets J Biol Chem 273 1998 2030 2034
17. J. Geiger, J. Brich, P. Honig-Liedl Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel Arterioscler Thromb Vasc Biol 19 1999 2007 2011
18. P.B. Conley, S.M. Delaney Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis Curr Opin Hematol 10 2003 333 338
19. R.T. Dorsam, S.P. Kunapuli Central role of the P2Y12 receptor in platelet activation J Clin Invest 113 2004 340 345
20. T.A. Clarke, L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
21. J.M. Pereillo, M. Maftouh, A. Andrieu Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
22. Z. Ding, S. Kim, R.T. Dorsam, J. Jin, S.P. Kunapuli Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270 Blood 101 2003 3908 3914
23. J.J. Thebault, G. Kieffer, G.D. Lowe, W.S. Nimmo, R. Cariou Repeated-dose pharmacodynamics of clopidogrel in healthy subjects Semin Thromb Hemost 25 Suppl 2 1999 9 14
24. J.J. Thebault, G. Kieffer, R. Cariou Single-dose pharmacodynamics of clopidogrel Semin Thromb Hemost 25 Suppl 2 1999 3 8
25. M. Savcic, J. Hauert, F. Bachmann, P.J. Wyld, B. Geudelin, R. Cariou Clopidogrel loading dose regimens kinetic profile of pharmacodynamic response in healthy subjects Semin Thromb Hemost 25 Suppl 2 1999 15 19
26. M.J. Quinn, D.L. Bhatt, F. Zidar Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention Am J Cardiol 93 2004 679 684
27. D.P. Vivekananthan, D.L. Bhatt, D.P. Chew Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention Am J Cardiol 94 2004 358 360
28. Z. Xiao, P. Theroux Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome J Am Coll Cardiol 43 2004 1982 1988
29. S.D. Wiviott, E.M. Antman Clopidogrel resistance a new chapter in a fast-moving story Circulation 109 2004 3064 3067
30. J.E. Mobley, S.J. Bresee, D.C. Wortham, R.M. Craft, C.C. Snider, R.C. Carroll Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization Am J Cardiol 93 2004 456 458
31. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo Platelet aggregation according to body mass index in patients undergoing coronary stenting should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16 2004 169 174
32. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
33. N.S. Nicholson, S.G. Panzer-Knodle, N.F. Haas Assessment of platelet function assays Am Heart J 135 1998 S170 S178
34. A.D. Michelson Platelet function testing in cardiovascular diseases Circulation 110 2004 e489 e493
35. M. Cattaneo Aspirin and clopidogrel efficacy, safety, and the issue of drug resistance Arterioscler Thromb Vasc Biol 24 2004 1980 1987
36. M.L. Rand, R. Leung, M.A. Packham Platelet function assays Transfus Apheresis Sci 28 2003 307 317
37. H.J. Seyfarth, M. Koksch, G. Roethig Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation Am Heart J 143 2002 118 123
38. I. Muller, M. Seyfarth, S. Rudiger Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93
39. D.C. Mills, R. Puri, C.J. Hu Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase Arterioscler Thromb 12 1992 430 436
40. R.R. Makkar, N.L. Eigler, S. Kaul Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis Eur Heart J 19 1998 1538 1546
41. A. Lepantalo, K.S. Virtanen, J. Heikkila, U. Wartiovaara, R. Lassila Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions Eur Heart J 25 2004 476 483
42. W.M. Samara, K.P. Bliden, U.S. Tantry, P.A. Gurbel The difference between clopidogrel responsiveness and posttreatment platelet reactivity Thromb Res 115 2005 89 94
43. P. Barragan, J.L. Bouvier, P.O. Roquebert Resistance to thienopyridines clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 59 2003 295 302
44. S. Matetzky, B. Shenkman, V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
45. B. Boneu, G. Destelle Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients Thromb Haemost 76 1996 939 943
46. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo High clopidogrel loading dose during coronary stenting effects on drug response and interindividual variability Eur Heart J 25 2004 1903 1910
47. C. Transon, T. Leemann, P. Dayer In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors Eur J Clin Pharmacol 50 1996 209 215
48. D. Williams, J. Feely Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacokinet 41 2002 343 370
49. W. Jacobsen, B. Kuhn, A. Soldner Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab Dispos 28 2000 1369 1378
50. W.C. Lau, L.A. Waskell, P.B. Watkins Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation a new drug-drug interaction Circulation 107 2003 32 37
51. H. Neubauer, B. Gunesdogan, C. Hanefeld, M. Spiecker, A. Mugge Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study Eur Heart J 24 2003 1744 1749
52. V.L. Serebruany, A.I. Malinin, K.P. Callahan, P.A. Gurbel, S.R. Steinhubl Statins do not affect platelet inhibition with clopidogrel during coronary stenting Atherosclerosis 159 2001 239 241
53. J. Saw, S.R. Steinhubl, P.B. Berger Lack of adverse clopidogrel- atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
54. H. Wienbergen, A.K. Gitt, R. Schiele Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies Am J Cardiol 92 2003 285 288
55. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg, M. Gawaz Effects of statins on platelet inhibition by a high loading dose of clopidogrel Circulation 108 2003 2195 2197
56. J.V. Mitsios, A.I. Papathanasiou, F.I. Rodis, M. Elisaf, J.A. Goudevenos, A.D. Tselepis Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes Circulation 109 2004 1335 1338
57. V.L. Serebruany, M.G. Midei, A.I. Malinin Absence of interaction between atorvastatin or other statins and clopidogrel results from the interaction study Arch Intern Med 164 2004 2051 2057
58. O. Gorchakova, N. von Beckerath, M. Gawaz Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting Eur Heart J 25 2004 1898 1902
59. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
60. W.E. Evans, H.L. McLeod Pharmacogenomics--drug disposition, drug targets, and side effects N Engl J Med 348 2003 538 549
61. M. Cattaneo, M.L. Zighetti, R. Lombardi Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding Proc Natl Acad Sci USA 100 2003 1978 1983
62. P. Fontana, A. Dupont, S. Gandrille Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995
63. P. Fontana, P. Gaussem, M. Aiach, J.N. Fiessinger, J. Emmerich, J.L. Reny P2Y12 H2 haplotype is associated with peripheral arterial disease a case-control study Circulation 108 2003 2971 2973
64. W.C. Lau, P.A. Gurbel, P.B. Watkins Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
65. J.K. Lamba, Y.S. Lin, E.G. Schuetz, K.E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271 1294
66. L. Wojnowski Genetics of the variable expression of CYP3A in humans Ther Drug Monit 26 2004 192 199
67. H.G. Xie, A.J. Wood, R.B. Kim, C.M. Stein, G.R. Wilkinson Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 5 2004 243 272